Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed large B-cell lymphoma
• •* Stage I, II, III, or IV disease
• •* Bone marrow or lymph node involvement by small cell lymphoma allowed
• •* No serious, progressive pathology (at investigator's discretion)
• •CD20-positive disease
• •Measurable disease
• •No prior indolent lymphoma, treated or not
• •No meningeal or CNS lymphoma
• •PATIENT CHARACTERISTICS:
• •International prognostic index \< 2 (adjusted for age)
• •Life expectancy \> 3 months
• •ALT and AST ≤ 2.5 times upper limit of normal
• •Bilirubin ≤ 30 mmol/L
• •Creatinine ≤ 150 μmol/L
• •HIV, hepatitis B virus, and hepatitis C virus negative (unless after vaccine)
• •No contraindication to chemotherapy or immunotherapy
• •No cancer in the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix
• •No contraindication to a venous catheter
• •PRIOR CONCURRENT THERAPY:
• •See Disease Characteristics
• •At least 30 days since prior and no other concurrent investigational treatment
• •No prior therapy
• •No concurrent participation in another clinical study